Berenberg Bank upgraded shares of Johnson Matthey (OTCMKTS:JMPLY – Free Report) from a hold rating to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.
A number of other research firms also recently commented on JMPLY. Citigroup reaffirmed a “neutral” rating on shares of Johnson Matthey in a research note on Tuesday, October 21st. Jefferies Financial Group upgraded shares of Johnson Matthey to a “strong-buy” rating in a report on Thursday, October 9th. Finally, Zacks Research downgraded shares of Johnson Matthey from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.
Read Our Latest Stock Report on JMPLY
Johnson Matthey Trading Down 1.1%
Johnson Matthey Announces Dividend
The firm also recently declared a dividend, which will be paid on Friday, February 13th. Investors of record on Tuesday, December 2nd will be issued a $0.5561 dividend. The ex-dividend date is Monday, December 1st. This represents a yield of 394.0%.
About Johnson Matthey
Johnson Matthey plc is a UK-based specialty chemicals and sustainable technologies company with a history dating back to 1817. As a public limited company headquartered in London, it has built a global reputation for expertise in platinum group metals (PGMs) and advanced catalytic materials. The company has evolved from its origins in precious metals refining into diversified segments focused on environmental and energy solutions.
The company’s principal business activities encompass the development and manufacture of emission control catalysts for the automotive and industrial sectors, alongside process technologies for chemical production and refining.
Read More
- Five stocks we like better than Johnson Matthey
- You Still Think Silver’s a Joke? Watch What Happens Next.
- A U.S. “birthright” claim worth trillions – activated quietly
- A month before the crash
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- YDES Could Be 2026’s Biotech Breakthrough
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.
